Kyowa Kirin Co., Ltd.

4151.T
Drug Manufacturers - Specialty & Generic
2026/03/02 Updated
Market Cap: $9.7B (¥1.5T)
Stock Price: $18.49 (¥2,885)
Exchange Rate: 1 USD = ¥156.01

(Correction) Partial Correction of “Financial Summary Supplementary Materials – Fiscal Year Ending December 2025 -“

Partial corrections were made in the supplementary financial summary for the fiscal year ending December 2025 regarding consolidated results, capital investment and intangible asset investment amounts, and product- and region-specific revenues.

Importance:
Page Updated: February 27, 2026
IR Disclosure Date: February 27, 2026

Key Figures

  • Revenue: 496.8 billion yen (Fiscal Year 2025 results)
  • Core Operating Income: 103.1 billion yen (Year-over-Year +8%)
  • Net Income Attributable to Owners of Parent (Quarter): 67.0 billion yen (Year-over-Year +12%)

AI要約

Overview of Corrections

An error was identified in the "Financial Summary Supplementary Materials - Fiscal Year Ending December 2025 -" announced on February 9, 2026, prompting partial corrections to consolidated results, capital and intangible asset investments, product-specific revenues, and region-specific revenues. Corrections are indicated by red underlines within the document.

Fiscal Year 2025 Earnings Overview

Revenue stood at 496.8 billion yen, nearly flat with a 13 billion yen (0.3%) year-over-year increase. Core operating income rose to 103.1 billion yen, up 7.7 billion yen (8%) year-over-year, while net income for the period reached 67.0 billion yen, a 7.2 billion yen (12%) year-over-year increase. Capital investment amounted to 35.0 billion yen in tangible fixed assets and 48.1 billion yen in intangible assets. The annual dividend was 60 yen per share, maintaining a payout ratio of approximately 40%.

Revenue Trend (2024–2025)

Core Operating Income Trend (2024–2025)

Regional Revenue Breakdown (Fiscal Year 2025)

Major Product Revenue Trends (Crysvita, Poteligeo, Libmeldy)

Capital and Intangible Asset Investment Amounts (2024–2025)

This page uses AI to summarize IR materials from TDnet. Please refer to the original document for investment decisions.